Search Results
Results found for "Bristol Myers Squibb"
- Dr. Andrew Tobin | Dr. GPCR Ecosystem
Following a post-doctoral period at Bristol Myers Squibb in Princeton USA, Andrew returned to the UK
- Brian Arey: Discovering Signaling Bias at the FSH Receptor | Dr. GPCR Ecosystem
Brian Arey, Director of Mechanistic Pharmacology at Bristol-Myers Squibb, traces the origins of that Arey is Director of Mechanistic Pharmacology within the Discovery and Optimization organization at Bristol-Myers Squibb, where he leads research spanning GPCR pharmacology, enzymology, and protein homeostasis pathways Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery and Optimization at Bristol-Myers Squibb Co . in Lawrenceville, NJ.
- Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem
Previously, she held the position of Vice President of Cell Biology & Pharmacology, at Bristol-Myers Squibb .
- Brian Arey - Part 2: GPCR Drug Discovery and the Science Nobody Publishes | Dr. GPCR Ecosystem
Arey is a pharmacologist and physiologist with over 25 years of pharmaceutical research experience at Bristol-Myers Squibb. Brian Arey is Senior Director of Mechanistic Pharmacology within Leads Discovery and Optimization at Bristol-Myers Squibb Co . in Lawrenceville, NJ.
- Dr. Benjamin Myers | Dr. GPCR Ecosystem
Benjamin Myers About Dr. Benjamin Myers Ben Myers is an assistant professor at the University of Utah School of Medicine in Salt Benjamin Myers on the web Website Twitter Pubmed University of Utah Dr.
- Dr. Paul J. Gasser | Dr. GPCR Ecosystem
My postdoctoral work, conducted at the University of Bristol, UK, in Christopher Lowry's lab, examined
- Dr. Mark Connor | Dr. GPCR Ecosystem
Postdoc with Graeme Henderson (Bristol, opioids and Ca signaling) and Mac Christie (Sydney, opioids in
- Chris Tate: Thermostabilizing GPCRs for Structural Biology | Dr. GPCR Ecosystem
Chris Tate obtained his Ph.D. from the University of Bristol in 1989 and then moved to the University
- Yamina's Corner | Dr. GPCR Ecosystem
Abishek Iyer, CEO Ashta Therapeutics Before working with Yamina, we had solid internal momentum but needed









